Press releases
- BrainStorm Cell Therapeutics to Present New Biomarker Data Suggesting ALS Patients May Benefit From Longer-Term Treatment with NurOwn
- BrainStorm Cell Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
- BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn
- BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule
- BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS
- BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS
- BrainStorm Cell Therapeutics to Provide Update on NurOwn Program
- BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update
- BrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn® Trial Design at MDA Clinical and Scientific Conference
- BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn® in ALS
More ▼
Key statistics
On Wednesday, Brainstorm Cell Therapeutics Inc (GHDN:DUS) closed at 0.539, 308.33% above the 52 week low of 0.132 set on Oct 24, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.542 |
---|---|
High | 0.590 |
Low | 0.539 |
Bid | 0.514 |
Offer | 0.549 |
Previous close | 0.539 |
Average volume | 15.00 |
---|---|
Shares outstanding | 70.08m |
Free float | 60.77m |
P/E (TTM) | -- |
Market cap | 43.45m USD |
EPS (TTM) | -0.3227 USD |
Data delayed at least 15 minutes, as of May 22 2024 18:31 BST.
More ▼